Alambic Investment Management L.P. lifted its holdings in shares of NewLink Genetics Corp (NASDAQ:NLNK) by 593.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 366,995 shares of the biotechnology company’s stock after acquiring an additional 314,095 shares during the quarter. Alambic Investment Management L.P. owned 0.99% of NewLink Genetics worth $1,747,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. increased its position in shares of NewLink Genetics by 0.8% during the second quarter. BlackRock Inc. now owns 2,279,452 shares of the biotechnology company’s stock valued at $10,850,000 after acquiring an additional 18,461 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of NewLink Genetics by 20.5% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 673,885 shares of the biotechnology company’s stock valued at $3,208,000 after acquiring an additional 114,650 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of NewLink Genetics by 6,778.1% during the first quarter. JPMorgan Chase & Co. now owns 493,367 shares of the biotechnology company’s stock valued at $3,577,000 after acquiring an additional 486,194 shares during the last quarter. Wells Fargo & Company MN grew its holdings in NewLink Genetics by 10.8% during the first quarter. Wells Fargo & Company MN now owns 413,905 shares of the biotechnology company’s stock valued at $3,001,000 after purchasing an additional 40,223 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in NewLink Genetics by 125.8% during the second quarter. Renaissance Technologies LLC now owns 405,100 shares of the biotechnology company’s stock valued at $1,928,000 after purchasing an additional 225,668 shares during the period. 42.01% of the stock is owned by institutional investors.

In other NewLink Genetics news, Director Ernest Talarico III sold 13,806 shares of the stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $4.82, for a total transaction of $66,544.92. Following the completion of the transaction, the director now directly owns 39,365 shares of the company’s stock, valued at $189,739.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 12.30% of the stock is currently owned by corporate insiders.

Several equities analysts have weighed in on the company. ValuEngine raised NewLink Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 16th. Zacks Investment Research lowered NewLink Genetics from a “buy” rating to a “hold” rating in a report on Thursday, June 7th. Finally, Stifel Nicolaus lowered NewLink Genetics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $8.00 to $4.00 in a report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. NewLink Genetics presently has an average rating of “Hold” and an average target price of $9.64.

Shares of NASDAQ NLNK opened at $3.01 on Friday. NewLink Genetics Corp has a 1-year low of $2.65 and a 1-year high of $19.30. The firm has a market cap of $111.27 million, a price-to-earnings ratio of -1.31 and a beta of 1.29.

NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings data on Tuesday, July 31st. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.12. NewLink Genetics had a negative return on equity of 53.70% and a negative net margin of 252.18%. The business had revenue of $2.25 million during the quarter, compared to analyst estimates of $5.85 million. equities research analysts predict that NewLink Genetics Corp will post -1.69 EPS for the current year.

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Featured Article: How do investors use RSI to grade stocks?

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.